Ankylosing spondylitis (AS) is an autoimmune disease. In addition, genetics have been considered the main cause of the disease. Since there is still no cure for AS, only drugs, exercises, and surgery can be used to delay the worsening of symptoms.
Drug repositioning refers to the search for compounds that are already on the market or in the advanced clinical stage. The indication may be other diseases, but it may also be used to treat other new indications.
We expect to spend 36 months exploring the difference between the susceptibility gene of AS between the Taiwanese ethnic group and European whites and screening out new potential drug candidates for treatment from existing or research drugs.
Based on the results of genetic testing, clinicians can give patients medication recommendations that better meet individual needs.
Repositioning drugs to find potential drugs that can treat ankylosing spondylitis from existing drugs can provide new treatment options.